Mitomycin-ifosfamide-cisplatinum (MIP) vs MIP-interferon vs cisplatinum-carboplatin in metastatic non-small-cell lung cancer: a FONICAP randomised phase II study. Italian Lung Cancer Task Force. by Ardizzoni, A. et al.
Brsilh J=v f dCancer (199) 7L 115-119
© 1995 Stocktn Press All rghts reserved 0007-0920/95 $9.00
Mitomycin-ifosfamide- cisplatinum (MIP) vs MIP- interferon vs
cisplatinum-carboplatin in metastatic non-small-cell lung cancer: a
FONICAP randomised phase II study
A Ardizzoni', GF Addamol, E Baldini2, U Borghini3, L Portalone4, F De Mannis4, R Lionetto5,
PF Conte', P Bruzzi5, MC Pennuccil, M Venturinil, M Rinaldi6, R Rosso' and F Salvati4 for the
Italian Lung Cancer Task Force (FONICAP)
'Department ofMedical Oncology I, Istituto Nazionale per la Ricerca sul Cancro, V. le Benedetto XV, 10 16132 Genoa;
-Department ofMedical Oncologv, S. Chiara Hospital, Pisa; 3Department ofPnewnology, Niguarda Hospital, Milano;
4Department ofPneuomology, Forlanini Hospital, Roma; 5Ctinical Epidemiology Unit, Istituto Na-ionale per la Ricerca sul
Cancro, Genova; 6Department ofMedical Oncology, Regina Elena Institute, Roma, Italv.
S_mmary The FONICAP group is screening, with randomised phase II studies. the activity of new
chemotherapy programmes for advanced non-small-cell lung cancer (NSCLC) looking for regimens with
>30% activity. In the present study. three regimens were tested: MIP (mitomycin 6mgm-2, ifosfamide
3 m-, cisplatinum 80mg m-2 on day every 28 days); MIP-IFN (MIP and interferon alpha-2b 3 MU s.c.
three times a week); and PC (cisplatinum 60 mg m-' and carboplatin 400 mg m on day I every 28 days).
Overall 93 chemotherapy-naive patients were enrolled: 23 received MIP, 27 received MIP-IFN and 43
received PC. Eighty per cent of the patients had stage IV and 20% stage Illb disease (positive pleural effusion
or supraclavicular nodes). Response rates were as follows: MIP = 9% (95% CI 1-28%), MIP-IFN = 7%
(95% CI 1-24%) and PC = 14% (95% CI 5-28%). The overal median survival was 183 days. Grade III-IV
leucopenia was observed in 36% of patients treated with MIP-IFN vs 10% in the other two arms, and
thrombocytopenia grade III-IV was reported in nearly 10% of patients overall. In conclusion, (1) all three
regimens investigated have poor activity (<30%); (2) when tested in multicentre randomised phase II trials.
MIP displays lower activity than in phase II trials; (3) PC has similar activity to other platinum-containing
regimens; (4) randomised phase II studies are a reliable and quick method of determining the anti-tumour
activity of novel chemotherapeutic regimens in NSCLC.
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Although more than 50 agents have been tested in the last
two decades, only a few of them have demonstrated discern-
ible anti-tumour activity in the treatment of advanced-stage
non-small-cell lung cancer (NSCLC). These antineoplastic
drugs, including cisplatinum (CDDP), ifosfamide (IFX),
mitomycin C (MMC), vindesine (VDS), vinblastine (VLB)
and etoposide (VP16), produce 5-20% objective response
rates when administered as single agents. Their use in com-
bination regimens allows an increase in the objective response
rate (20-40%) to be obtained without a detectable improve-
ment in the survival outcome. Randomised phase III studies
comparing the activity of the different chemotherapy pro-
grammes available have led to the conclusion that the known
two- and three-drug regimens, including intermediate/high-
dose CDDP, have similar efficacy (Ihde, 1992). Furthermore,
the activity of these regimens in randomised multicentre
phase III trials usually turns out to be lower than anticipated
from the results of single-institution phase II studies (Ein-
horn et al., 1986). Therefore, at the present time, it appears
that the demonstration of significant activity in an uncon-
trolled phase II trial, often carried out in a very selected
patient population, is not sufficient to warrant the initiation
of an expensive and time-consuming large randomised phase
III trial.
Based on these considerations, in 1991 the Italian Lung
Cancer Task Force (FONICAP) started a policy of screening
and verification of the anti-tumour activity of new and pro-
mising chemotherapy regimens or single agents with con-
secutive multicentre phase II randomised trials. This study
design should allow us to overcome the selection bias most
likely responsible for the overestimation of chemotherapy
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activity in non-randomised phase II studies. Only those pro-
grammes which show significant anti-tumour activity in this
setting may deserve to be compared with standard treatments
in phase III studies. The present study was aimed at assessing
the activity and toxicity of three CDDP-containing chemo-
therapies: MMC-IFX-CDDP (MIP), MIP combined with
recombinant interferon alpha (MIP-IFN) and carboplatin-
CDDP (CP).
In the first arm, we aimed at verifying the activity of MIP,
which showed a high level of activity in four non-randomised
phase II studies (37-69% response rate) (Giron et al., 1987;
Cullen et al., 1988; Currie et al.. 1990; Mariani et al., 1991).
Recombinant interferon (IFN) was added to MIP in the
second arm of the study according to the hypothesis resulting
from a previous randomised phase III trial of our group
(Ardizzoni et al., 1993), suggesting a possible potentiating
effect of IFN on CDDP-containing chemotherapy.
The third arm, in view of the single-agent activity, different
toxicity profile and incomplete cross-resistance of the two
agents, consisted of a combination of carboplatin (CBDCA)
and CDDP in an attempt to administer a 'high-dose




Eligible patients were required to have histologically or
cytologically confirmed NSCLC, stage IV disease or stage
IlIb disease with either supraclavicular node involvement or
malignant pleural effusion and disease previously untreated
with chemotherapy. Prior radiotherapy was allowed only if
delivered outside the target lesion evaluable for response. The
presence of at least one bidimensionally measurable lesion
(target lesion) was considered mandatory. The following wereRins hd N -ed d pId. y m..mw NSC
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considered exclusion criteria: age>70 years, ECOG perfor-
mance status>2, life expectancy<2 months, active CNS
disorder or known brain metastases, inadequate haemato-
logical function (WBC<4000mmn3, platelet count<
100000mm-3), abnormal renal function (creatnine ckar-
ance<60 ml min-' and serum creatinine> 1.2) or hepatic
function (total bilirubin> 1.2 mgdl-'), cardiovascular dis-
ease (cardiac failure, myocardial infarction within the
previous 3 months, uncontrolld hypertension or arrhyth-
mias). Patients with previous or concomitant neoplasms
(other than in situ cervical or cutaneous basal cell cancer)
were also excluded. Eligible patients gave oral or written
informed consent according to the guidelines of each par-
ticipating centre.
Assessment
At entry a complete medical history was obtained, clinical
and physical examination (incxluding assessment of weight
oss in the lasts 6 months and of performance status) was
performed and the following laboratory tests were carried
out: WBC (total and differential), RBC and platelet counts,
Hb, glutamic oxaloacetic transamias (GOT) and ghamic
pyruvic transai (GPT), alkaline phosphatase (ALP),
gamma-glutamyltransferase (7-GT), lactate dehydrogenase
(LDH), bilirubin, glucose, blood urea nitrogen (BUN), unc
acid, creatinine and creatinine ckarance, total protein and
albumin CEA, sodium, potassium, calcium, phosphorus and
magnesium. The following instrumental tests were performed:
ECG, chest radiography, chest computerised tomography
(Cl) scan or conventional chest tomography, abdomen CT
scan or ultrasound; bone scan or bone X-ray survey and
brain CT scan were performed only ifmetastatic involvement
in these sites was clinically suspected. Weekly blood counts
were obtained only during the first course to assess nadir
haematological toxicity. At each cycle all patients underwent
physical examination, together with blood count and chemis-
try. The assessment of measurable lesions was performed
every other cycle. The evaluation of all measurable lesions
had to be performed with the same technique used to
measure the lesion before enrolment into the study. When a
patient ceased treatment because of treatment failure, tox-
icity, refusal or other reasons, a full assessment was per-
formed.
Treatment
Patients were randomised to one of the following treatment
arms:
Arm A MMC 6mgm-2 i.v. on day 1
IFX 3gm2 i.v. on day 1
CDDP 80mgm-' i.v. on day 1
Mesna 600mgm-2 i.v. before IFX infusion and
1200mgm-2 p.o. 4 and 8h after IFX
Arm B The same as in arm A plus recombinant IFN-a-
2b 3 000000 IU subcutaneously daily from day
-2 to day + 3 then 3 days a week.
Arm C CDDP 60mgm-' i.v. on day 1
CBDCA 400mgm-2 i.v. on day I
Cycles were repeated every 28 days. In the case of incom-
plete haematologial recovery, treatment was delayed by 1
week. In the case ofnadir grade IV haematological toxicity, a
25% dose reduction was applied. All patients had to be given
at kast two courses of chemotherapy unless rapid progres-
sion, excessive toxicity or rapid clinical deterioration occur-
red. Treatment was continued for a maximum of six cycles
provided progression did not occur.
Cisplatinum, in the three treatment arms, was infused
rapidly over 15 min preceded by 500 ml ofnormal saline over
30min and followed by 1000ml of normal saline containing
1 g of magnesum sulphate over 60-90min- If diuresis was
<200 ml at the end of the infusion, furosemide 20mg i.v.
was administered, followed by 500 ml of normal sahne until
acceptable diuresis was achieved.
Evaluation ofresponse and toxicity
The evaluation of response was performed every two cycles
according to the WHO criteria: complete response (CR) was
considered as complete disappearance of all tumour deter-
mined by two observations not less than 4 weeks apart.
Partial response (PR) was a >50% decrease in the cross-
sectional areas of the measurable lesions in the absnce of
progression in other sites or absence of appearance of new
lesions. Stable disease (SD) was a change in size of
measurabledisease by <25% with no appearance of new
lesions. Responses were blindly reviewed by a group of five
physicans vting the partwipatmg centres.
Side-effects of treatment were graded according to the
WHO scale and evaluated at the time of repeat cycles.
Statistical analysis
A centralised telephone call procedure was used to assign
patients randomly to treatment groups, and allocation to
each treatment arm was made from a computer-generated
lst, stratified according to centre.
This was a phase H randomised trial run with the aim of
screening chemotherapy combinations that show promising
anti-tumour activity and therefore justify further trials. As a
consequence, comparisons of the three arms were not plan-
ned. The main end point was response rate.
We adopted Simon's optimal two-stage design for phase H
clinical trials to caculate the sample size that minimises the
expected number of patients to be accrued if a combination
had low activity (Simon, 1989).
Tlhe sample size was calculated on the following assum-
ptions: alpha error = 0.05, beta error = .10, P. (clinically
uninteresting true response rate) and P, (sufficiently promis-
ing true response rate), defined according to Simon (1989)
were set at 10% and 30% respectively. In each arm 18
patients had to be randomised in the first stage. If <2
responses were observed, the accrual was stopped and the
drug combination rejected. In the case of >2 responses, 17
more patients had to be accrued. The drug combination had
to be accepted if >7 responses out of 35 evaluable patients
were observed.
All randomised patients were included in the final analysis
of response rate on an 'intention to treat' basis, thereby
including also early deaths and early progressions.
Resdt
Patient demographics
Ninety-three patients were entered into the study from 12
Italian institutions. The characteristics of patients are shown
in Table I. Accrual in arms A and B was stopped at the first
stage as the minimum number of responses required to pro-
ceed to the second stage of the study was not achieved. By
the time the first 18 patients had all been evaluated for
response, a total of 23 and 27 had been enrolled in arms A
and B respectively. Patient intake in arm C could proceed
through the second stage and, as a consequence, 43 patients
were randomised in this arm of the study.
The majority of patients were males (nearly 90%), were
ambulatory (ECOG performance status 0-1) and had stage
IV disease. Median age was 61 years in arm A (range
32-70), 60 years in arm B (range 39-70) and 62 years in arm
C (range 36-70). There was a slight disproportion in favour
of arm A in terms of stage (Ilb vs IV) and histology
(squamous vs adenocarcinoma). The most frequent sites of
metastases were bone (41%), superficial nodes (29%), lung
(23%) and adrenals (18%).
Analysis ofactivity
All randomised patients were included in the response
analysis, according to the 'intention to treat' principle.PAndomisW - 11 stdy ofpb*mm-basedArbzmms t NlLC
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Detailed response data for each of the treatment arm are
shown in Table II.
The overall response rates (complete plus partial remis-
sions) were as follows: arm A= 2/23 (8.8%, 95% CI =
1-28%), arm B = 2/27 (7.4%, 95% CI = 1-24), arm C = 6/
43 (14%, 95% CI 5-28%).
Eighteen of the 93 randomised patients could not be
evaluated for response because of inadequate follow-up (two
cases), inadequate documentation of response (eight cases) or
protocol violation (four patients). Two patients refused treat-
ment and two patients stopped treatment for toxicity. All
these unevaluable patients were recorded as non-responders.
Considering only those patients adequately treated and
evaluated, response rates were 11.8%, 9.5% and 16.2% in
arms A, B and C respectively.
The overall actuarial median survival was 183 days (Figure
1).
WHO performance status score after two treatment cycles
could be compared with the baseline in 12, 16 and 30
patients in arms A, B and C respectively. Overall, among 29
patients whose pretreatment PS score was 1 or 2, there were
six cases (20%) with an improvement of one grade of their
PS score. Interestingly, only two out of six patients had a
corresponding objective response to treatment.
'Delivered' and 'planned' dose intensity were calculated at
the second and fourth cycle using the standard methodology
(Hryniuk, 1984). At the second cycle 14, 17 and 31 patients
in arms A, B and C, respectively, could be evaluated for the
calculation of dose intensity. All these patients actually
received more than 60% of the planned dose intensity. The
Table I Patient's characteristics
Per cent ofpatients
MIP MIP + IFN CDDP + CBDCA
(n = 23) (n = 27) (n = 43)
Stage
III B 34.8 11.1 18.6
IV 65.2 88.9 81.4
Age
<60 47.8 44.4 34.9
.60 52.2 55.6 65.1
Histology
Squamous 47.8 29.6 41.9
Adenocarcinoma 30.4 51.9 48.8
Large cell 8.7 18.5 2.3
PS
<2 78.2 77.7 88.4
. 2 8.8 14.8 11.6
Sex
Male 87.0 88.9 88.4
Female 13.0 11.1 11.6
Weight loss
. 10% 4.3 7.4 14.0
< 10% 43.5 40.7 27.9
No 43.5 48.1 41.9
mean dose intensity of MIP actually delivered in arm A was
.80% of the planned dose intensity in 13/14 patients. The
figure was only slightly lower (13/17 had .80% dose inten-
sity) in arm B, probably because of IFN-related haemato-
logical toxicity. In arm C, >,80% of the planned
CDDP-CBDCA average dose intensity was delivered to 19/
31 patients. Dose intensity results for the fourth course were
superimposable.
Toxicity
Treatment toxicity was evaluable in 86 patients. The main
treatment side-effects are summarised in Table III.
The incidence of life-threatening toxicity was limited, with
only one case of severe nephrotoxicity in arm B and almost
negligible neurotoxicity.
Toxicity was, in general, more frequent in arm B. IFN, in
addition to producing its typical toxicities (fever, asthenia,
anorexia, flu-like syndrome), resulted in a worsening of
chemotherapy side-effects (grade 3-4 vomiting and






Fugwe I Overall survival. Median time to survival = 183.2 days.
Table HI Treatment toxicitya
Per cent ofpatients
MIP MIP + IFN CDDP + CBDCA
(n = 21) (n = 25) (n=40)
WHO grade 1-2 3-4 1-2 3-4 1-2 3-4
Nausea/vomiting 76.2 19.0 68.0 32.0 67.5 7.5
Alopecia 42.8 23.0 52.0 20.0 45.0 -
Mucositis 28.6 - 12.0 - 12.5 -
Diarrhoea 4.8 - 16.0 - 7.5 -
Fever 14.3 - 68.0 4.0 20.0 5.0
Constitutional - - 36.0 4.0 7.5 -
Asthenia 66.7 9.5 76.0 20.0 50.0 7.5
Anorexia 66.7 4.7 72.0 20.0 47.5 10.0
Leucopeia 47.6 9.5 20.0 36.0 17.5 10.0
Thrombocytopenia - 4.8 24.0 12.0 25.0 10.0
Anaemia 19.0 - 36.0 8.0 22.5 7.5
'Worst toxicity observed per patient.
Table H Response to treatment
Per cent ofpatients
MIP MIP + IFN CDDP + CBDCA
(n=23) (n = 27) (n =43)
Complete response - 3.7 12.4
Partial response 8.8 3.7 11.6
Stable disease 21.8 37.0 30.2
Progressive disease 17.4 14.4 30.2
Early progression of death 26.0 18.5 11.7
Inadequate follow-up - - 4.7
Protocol violation 4.3 7.4 2.3
Early interruption for toxicity 4.3 3.7
Inadequate radiological 17.5 7.5 4.7
documentation of response
Treatment refusal - 3.7 2.3
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cisplatinum was the best-tolerated treatment: among 40
evaluable patients, we observed only three cases ofgrade 3-4
vomiting, 10% grade 3-4 thrombocytopenia and evident
alopecia was virtually absent.
The three platinum-based chemotherapy regimens under
investigation displayed poor anti-tumour activity in this ran-
domised phase II study. The low response rate achieved
could not be attributetd to inadquacy of dose intensity or
study quality. These new chemotherapy combinations do not
seem to represent a step forward compared with stand
chemotherapy regimens, since the study had a 90% power
against the alternative hypothesis of an activity of 30% in
metastatic NSCLC. Therefore, it does not seem justified to
explore them further and launch randomised phase m
studie comparing the outcome ofpatients treated with these
novel combinations vs standard regimes.
The activity of MIP was lower than that reported in
previous studies. In fact, the response rate of MIP in non-
randomised phase II studies (Giron et al., 1987; Cullen et al.,
1988; Currie et al., 1990; Mariani et al., 1991) was always
reported to be greater than 30% (37-69%) whereas, in the
present study, the anti-tumour activity was clearly lower.
This discrepancy may arise for a number of reasons: the
selection of patients with more advanced disease (higher
proportion of patients with stage IV disease), the strict
methodology used to assess response and the use of an
"intention to treat' analysis (unevaluable patients were
included in the denominator for aculating major response
rate). However, it is our opinion that MWP activity was
overestimated in previous phase H studies, as is often the
case for single-institution phase II compared with multicentre
phase Il studies (Einhorn et al., 1986). This strengthens the
validity ofthe randomised phase H design as a more reliable
tool to screen the activity of novel treatments. There are
many advantages with studies of this type. Firsty, ran-
domisation ensures that patients are centrally registered
before treatment starts. This is essential to check eligibility
and to ensure that all patients enroLled are reported upon.
Second, patient selection, response criteria, dose modifica-
tions and reporting procedures are homogeneous among the
participating centres. Finally, the central rview of radio-
logical material allows the inter-observer vanability in res-
ponse asssment to be reduced.
The addition of IFN to MIP did not improve the response
rate. This is in contrast to one of our previous randomised
studies, which showed an increased response rate when IFN
was added to PEC chemotherapy (8.7% vs 21.5%) (Ardiz-
zoni et al., 1993). Given the low activity of PEC in that
study, we aimed at exploring the potentiating activity of IFN
with a more recent, and presumably more active, regimen.
However, the results ofthe present study would not suggest a
potentiating effect of IFN on MIP chemotherapy. This might
be because of lower dose of IFN used in this study (3 MU
compared with 5 MU in the previous study).
CDDP and CBDCA possess similar single-agent activity in
advanced NSCLC (Bonomi et al., 1989) with different dose-
limiting toxicities. Although they share a common active
metabolite and therefore a common mechanism of anti-
tumour action, they have distic pharmacodynamics and
additive cytotoxicity in lung cancer cell lines (Hong et al.,
1985; Roed et al., 1988; Cohen et al., 1989). Therefore, in
theory, the combination ofCDDP and CBDCA might enable
the delivery of a high total dose of 'platinum' and an
enhanced tumour cell kill, without producing excessive addic-
tive toxcity. The activity of this combination in our study is
similar to that of other CDDP-containing rimens. Interest-
ingly, toxiity was unexpetdly mild, with only 10% of the
patients having grade 3-4 leucopenia or thrombocytopenia
and virtually no case of complete alopecia- Our results are
similar to those of two other studies. A CALGB phase II
trial reported a response rate of 13% among 76 extensive
NSCLC patients (Kreisman et al., 1990). Despite the use of
slightly higher chemotherapy doses than in the American
study, we observed a lower incidence of severe haemato-
logical toxicty. T-he European Lung Cancer Work-ing Party
has recently published the results of a phase H randomised
study of single-agent high-dose CDDP and moderate-dose
CDDP combined with CBDCA. Although 50% less CBDCA
was used in comparison with our study, they obtained a
slightly better response rate (21%) with superimposable tox-
icity among 53 eligible patients (Scuier et al., 1994).
Therefore, CBDCA dose does not seem to play a major role
in the activity and toxicity of the CDDP-CBDCA regimen.
In conclusion, none of the novel chemotherapy combina-
tions under investigation in the present randomised phase II
study appears to offer a significant therapeutic advantage
over standard chemotherapy programmes. The combination
of CBDCA and CDDP, given the low haematological and
non-haematologial toxicity, can be considered as an alterna-
tive to standard platinum-containing regimens. Phase II ran-
domised trials are a reliable and quick method of screening
and verifying the anti-tumour activity of novel agents or
combinations which may better orient the design of com-
parative phase III randomised studies in NSCLC.
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